Orkambi does not have a marketing authorisation in the United Kingdom for use in the treatment of children aged under 12 with cystic fibrosis. Where clinically appropriate and subject to the relevant commissioner making funding available, Orkambi may be prescribed as an off-label drug. Off-label prescribing is supported in guidance given to prescribers by both the General Medical Council and by the Medicines and Healthcare products Regulatory Agency.